BPA for rapivab, orladeyo
Ended Awarded Last action
- Contract number
- 36E79721A0015
- Awardee
-
Biocryst Pharmaceuticals Inc. UEI MGXADJ6SCLJ5
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $10,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Biocryst Pharmaceuticals Inc. was awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs National Acquisition Center on May 19, 2021, with a $10 million ceiling value and an ultimate completion date of May 18, 2026. This procurement vehicle, established under the Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, facilitates the delivery of two specialized pharmaceutical products: RAPIVAB (peramivir) for influenza treatment and ORLADEYO (berotralstat) for hereditary angioedema management. The BPA was awarded without a set-aside designation, indicating open market competition. The agreement enables the Veterans Affairs system to streamline procurement and expedite delivery of these critical medications across multiple Veterans Integrated Service Networks and federal healthcare facilities.
The BPA structure allows the Department of Veterans Affairs to issue delivery orders for RAPIVAB and ORLADEYO as needed, with pricing subject to 2026 Public Law updates to ensure competitive rates throughout the contract performance period. By consolidating procurement of these specialized rare disease treatments under a single-award indefinite delivery vehicle, the government achieves operational efficiency in supplying critical pharmaceutical interventions to the veteran population while maintaining a strategic partnership with a specialized biotechnology vendor. The contract's five-year performance window provides the Veterans Affairs system with reliable access to these medications while allowing for pricing adjustments to reflect market conditions and regulatory changes.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79721A0015?
36E79721A0015 was awarded to Biocryst Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on May 19, 2021.
How much is contract 36E79721A0015 worth?
36E79721A0015's own ceiling is $10,000,000.
Who can order from contract 36E79721A0015?
36E79721A0015 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79721A0015 under another contract?
Yes. 36E79721A0015 is a blanket purchase agreement under 36F79721D0166, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79721A0015 competed?
The extent of competition for 36E79721A0015 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV